Variant AAV2 Capsid for Neuronal Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adeno-associated virus (AAV) vectors for gene therapy lack improved properties for in vivo transgene expression and tissue specificity, particularly for targeting neuronal and retinal tissues, with a limited understanding of the molecular mechanisms underlying tissue tropism.
Innovation Solution
Development of recombinant AAV vectors with variant capsid proteins, such as AAV2, AAV8, and AAV3B, featuring specific amino acid substitutions at defined positions, enhancing transduction efficiency and specificity for neuronal or retinal tissues by modifying the capsid protein sequence to improve receptor binding and cellular uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild type AAV2 capsid protein is used, then the vector has basic transduction capability, but the transduction efficiency in neuronal and retinal tissues is insufficient
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions at defined positions (457, 492, 499, and 533) in the AAV2 capsid protein sequence. These substitutions (Q457M, S492A, E499D, F533Y) modify the physical-chemical properties of the capsid surface, thereby changing its binding affinity and specificity for neuronal and retinal tissue receptors, resulting in enhanced transduction efficiency in these target tissues.
Solution Approach 2:
The patent applies local quality by making targeted amino acid substitutions at specific positions (457, 492, 499, and 533) within the capsid protein sequence rather than uniform modifications throughout. These localized changes at critical surface residues selectively enhance interaction with neuronal and retinal tissue receptors while preserving overall capsid structure and function, achieving tissue-specific transduction improvement.
2Adaptability or versatility
If multiple amino acid substitutions are introduced to improve tissue specificity, then transduction efficiency in target tissues increases, but the complexity of vector design and production increases
Solution Approach 1:
The patent resolves this contradiction by changing specific parameters (amino acid residues) at precisely defined positions in the capsid protein sequence. Rather than random or comprehensive modifications, the invention focuses on substituting residues at four specific positions (457, 492, 499, 533), which simplifies the design process while achieving significant improvements in tissue specificity and transduction efficiency.
Solution Approach 2:
The patent applies local quality by concentrating modifications at specific critical positions within the capsid protein rather than distributing changes throughout the entire sequence. This localized approach at positions 457, 492, 499, and 533 reduces design complexity while maintaining the ability to achieve enhanced tissue-specific transduction through targeted receptor interactions.
Data Source
AI summary
Disclosed herein is a recombinant adeno-associated virus (AAV) vector comprising (a) a variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions with respect to a wild type AAV2 capsid protein; wherein the at least four amino acid substitutions are present at the following positions in an AAV2 capsid protein sequence: 457, 492, 499 and 533; and (b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.